109062-95-5

Basic information

• Product Name: 4-Cyclohexene-1,2-dicarboxylic acid, bis[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl] ester, (1S,2S)-
• CAS NO: 109062-95-5
• Molecular Formula: C28H46O4
• Molecular Weight: 446.671
• Mol File: 109062-95-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-Cyclohexene-1,2-dicarboxylic acid, bis[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl] ester, (1S,2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyclohexene-1,2-dicarboxylic acid, bis[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl] ester, (1S,2S)-(109062-95-5)
• EPA Substance Registry System: 4-Cyclohexene-1,2-dicarboxylic acid, bis[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl] ester, (1S,2S)-(109062-95-5)

Safety Data

• Hazardous Substances Data: 109062-95-5(Hazardous Substances Data)

Upstream product

• 34212-60-7 di-<(1R,2S,5R)-(-)-menthyl>maleate 
• 2216-51-5 (-)-menthol 
• 34675-24-6 di-L-menthyl fumarate 
• 106-99-0 buta-1,3-diene 
• 120143-40-0 (2Z,1'S,2'R,5'S)-but-2-enedioic acid bis(2'-isopropyl-5'methyl-cyclohexyl) ester 
• 15356-60-2 (1S,2R,5S)-(+)-menthol 
• 86287-64-1 (2E,1'S,2'R,5'S)-but-2-enedioic acid bis(2'-isopropyl-5'methyl-cyclohexyl) ester 

Downstream Products

• 15679-27-3 (4S,5S)-4,5-bis(hydroxymethyl)cyclohexene 
• 246518-22-9 (1S,3S,4S)-3-(benzyloxymethyl)-4-(hydroxymethyl)cyclopentanol 
• 246518-21-8 (3S,4S)-3-(benzyloxymethyl)-4-(hydroxymethyl)cyclopentanone 
• 67337-17-1 ((1S,6S)-6-(benzyloxymethyl)cyclohex-3-enyl)methanol 
• 58124-49-5 (5aS,9aS)-3-phenyl-1,5,5a,6,9,9a-hexahydrobenzo[e][1,3]dioxepine 
• 207129-36-0 [(2S,4S,5R)-2-hydroxymethyl-5-vinyl-2-quinuclidine] 
• 1365034-52-1 2-((2S,4R,5R)-2-((tert-butyldimethylsilyloxy)methyl)-5-(2-hydroxyethyl)-1-(2,2,2-trifluoroacetyl)piperidin-4-yl)ethyl benzoate 

Relevant articles and documents

ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF

The present invention relates to novel adenine based inhibitors of adenylyl cyclase of the formula: wherein X, L, R1, R2, R5 are those defined herein. Compounds of the present invention are useful to treat cardiovascular diseases. The present invention also relates to a method of preventing heart failure by administering an effective amount of compound according to the invention following vascular injury and reperfusion therapy.

Total synthesis of the polyenoyltetramic acid polycephalin C

The total synthesis of the polyenoyltetramic acid polycephalin C is described. Key steps of the synthesis include a double Swern oxidation, double Takai reaction and a double Stille reaction. In addition, the absolute stereochemistry of the ring junction

Synthesis and biological evaluation of a monocyclic, fully functional analogue of compactin

Compound 8, a monocyclic analogue of compactin, has been prepared and its efficacy as an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGR) evaluated. The synthesis (Schemes I and II) requires seven steps starting with di-(-)-menthyl fumar